Lipocine Receives Complete Response Letter for Tlando From U.S. Food and Drug Administration

SALT LAKE CITY, May 9, 2018 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company, announced today that it has received a Complete Response Letter ( " CRL " ) from the United States Food and Drug Administration ( " FDA " )...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news